RS62151B1 - Konstrukti koji sadrže sirp-alfa domen ili njegovu varijantu - Google Patents

Konstrukti koji sadrže sirp-alfa domen ili njegovu varijantu

Info

Publication number
RS62151B1
RS62151B1 RS20210912A RSP20210912A RS62151B1 RS 62151 B1 RS62151 B1 RS 62151B1 RS 20210912 A RS20210912 A RS 20210912A RS P20210912 A RSP20210912 A RS P20210912A RS 62151 B1 RS62151 B1 RS 62151B1
Authority
RS
Serbia
Prior art keywords
sirp
constructs
variant
alpha domain
alpha
Prior art date
Application number
RS20210912A
Other languages
English (en)
Inventor
Jaume Pons
Laura Deming
Corey Goodman
Bang Janet Sim
Steven Elliot Kauder
Hong Wan
Tracy Chia-Chien Kuo
Original Assignee
Alx Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alx Oncology Inc filed Critical Alx Oncology Inc
Publication of RS62151B1 publication Critical patent/RS62151B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596Molecules with a "CD"-designation not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • C07K14/765Serum albumin, e.g. HSA
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/524CH2 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/526CH3 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
RS20210912A 2015-08-07 2016-08-05 Konstrukti koji sadrže sirp-alfa domen ili njegovu varijantu RS62151B1 (sr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562202772P 2015-08-07 2015-08-07
US201562202779P 2015-08-07 2015-08-07
US201562202775P 2015-08-07 2015-08-07
US201562265887P 2015-12-10 2015-12-10
US201662276796P 2016-01-08 2016-01-08
US201662276801P 2016-01-08 2016-01-08
US201662346414P 2016-06-06 2016-06-06
EP16835723.4A EP3331902B1 (en) 2015-08-07 2016-08-05 Constructs having a sirp-alpha domain or variant thereof
PCT/US2016/045914 WO2017027422A1 (en) 2015-08-07 2016-08-05 Constructs having a sirp-alpha domain or variant thereof

Publications (1)

Publication Number Publication Date
RS62151B1 true RS62151B1 (sr) 2021-08-31

Family

ID=57983500

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20210912A RS62151B1 (sr) 2015-08-07 2016-08-05 Konstrukti koji sadrže sirp-alfa domen ili njegovu varijantu

Country Status (34)

Country Link
US (5) US10259859B2 (sr)
EP (2) EP3331902B1 (sr)
JP (3) JP6898303B2 (sr)
KR (1) KR20180028548A (sr)
CN (3) CN117777267A (sr)
AU (2) AU2016304794B2 (sr)
BR (1) BR112018001353A2 (sr)
CA (1) CA2993835A1 (sr)
CL (3) CL2018000340A1 (sr)
CO (1) CO2018002471A2 (sr)
CY (1) CY1124372T1 (sr)
DK (1) DK3331902T3 (sr)
ES (1) ES2881771T3 (sr)
GE (2) GEP20217326B (sr)
HK (1) HK1257372A1 (sr)
HR (1) HRP20211167T1 (sr)
HU (1) HUE055139T2 (sr)
IL (3) IL256989B (sr)
LT (1) LT3331902T (sr)
MX (2) MX2018001428A (sr)
MY (1) MY185014A (sr)
NZ (1) NZ738950A (sr)
PE (1) PE20180778A1 (sr)
PH (1) PH12018500269A1 (sr)
PL (1) PL3331902T3 (sr)
PT (1) PT3331902T (sr)
RS (1) RS62151B1 (sr)
RU (2) RU2740672C2 (sr)
SA (1) SA518390881B1 (sr)
SG (2) SG10202101909RA (sr)
SI (1) SI3331902T1 (sr)
UA (1) UA125638C2 (sr)
WO (1) WO2017027422A1 (sr)
ZA (3) ZA201800857B (sr)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10053513B2 (en) * 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
GEP20217326B (en) 2015-08-07 2021-11-25 Alx Oncology Inc Constructs having a sirp-alpha domain or variant thereof
US10894831B2 (en) 2015-08-26 2021-01-19 The Board Of Trustees Of The Leland Stanford Junior University Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist
EP4183451A1 (en) 2015-10-01 2023-05-24 Heat Biologics, Inc. Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
SG11201805894YA (en) 2016-01-11 2018-08-30 Forty Seven Inc Humanized, mouse or chimeric anti-cd47 monoclonal antibodies
US11560433B2 (en) 2016-05-27 2023-01-24 Albert Einstein College Of Medicine Methods of treatment by targeting VCAM1 and MAEA
BR112019002394B1 (pt) 2016-08-10 2021-12-21 Ajou University Industry-Academic Cooperation Foundation Proteína heterodimérica fundida com fc e seu uso
HRP20220230T1 (hr) 2017-01-05 2022-04-29 Kahr Medical Ltd. Sirp1 alfa-41bbl fuzijski protein i metoda njegove upotrebe
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
HRP20230937T1 (hr) 2017-01-05 2023-11-24 Kahr Medical Ltd. Pd1-41bbl fuzijski protein i metode korištenja istog
WO2018127916A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-cd70 fusion protein and methods of use thereof
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
AU2018223821B2 (en) 2017-02-27 2022-05-19 Shattuck Labs, Inc. TIGIT- and LIGHT-based chimeric proteins
EP3585409A4 (en) 2017-02-27 2020-12-02 Shattuck Labs, Inc. CHEMERICAL PROTEINS BASED ON CSF1R
WO2018176132A1 (en) * 2017-03-28 2018-10-04 Trillium Therapeutics Inc. Cd47 blockade therapy
TWI816673B (zh) * 2017-05-08 2023-10-01 大陸商上海津曼特生物科技有限公司 雙特異性重組蛋白及其應用
CA3102086A1 (en) * 2017-06-06 2018-12-13 Relinia, Inc. Single-chain tnf receptor 2 agonist fusion proteins
WO2019047885A1 (en) * 2017-09-07 2019-03-14 Dingfu Biotarget Co., Ltd. IMMUNOCONJUGATES COMPRISING ALPHA REGULATORY SIGNAL PROTEIN
JP7163399B2 (ja) * 2017-11-20 2022-10-31 泰州▲邁▼博太科▲薬▼▲業▼有限公司 Cd47とpd-l1を標的にする二重機能の融合タンパク質
KR20200093639A (ko) 2017-12-04 2020-08-05 북경한미약품 유한공사 천연 항체 구조-유사 헤테로다이머 형태의 항 pd-l1/항 cd47 이중특이성 항체 및 이의 제조
CN109971716B (zh) * 2017-12-28 2023-08-01 上海细胞治疗研究院 自分泌cd47抗体的egfr特异性car-t细胞及其用途
ES2927305T3 (es) 2018-02-12 2022-11-04 Forty Seven Inc Régimen contra el cáncer usando anticuerpos anti-CD47 y anti-CD20
US20210040224A1 (en) * 2018-03-13 2021-02-11 Trillium Therapeutics Inc. Cd47 blockade therapy with cd38 antibody
AU2019235627A1 (en) * 2018-03-13 2020-10-08 Pfizer Inc. Improvements in CD47 blockade therapy by EGFR antibody
CN110386984B (zh) * 2018-04-17 2022-04-22 杭州尚健生物技术有限公司 结合cd47蛋白的融合蛋白及其应用
JP2021524283A (ja) * 2018-05-17 2021-09-13 イムノーム、インコーポレイテッド Ch3ドメインエピトープタグ
KR20210029158A (ko) * 2018-06-03 2021-03-15 람카프 바이오 베타 엘티디. Ceacam5 및 cd47에 대한 이중특이성 항체
WO2020012486A1 (en) 2018-07-11 2020-01-16 Kahr Medical Ltd. SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
WO2020033646A1 (en) 2018-08-08 2020-02-13 Orionis Biosciences, Inc. SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
JP2021534769A (ja) * 2018-08-31 2021-12-16 エーエルエックス オンコロジー インコーポレイテッド デコイポリペプチド
TW202028237A (zh) 2018-09-27 2020-08-01 美商西建公司 SIRPα結合蛋白及其使用方法
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
CN109306017B (zh) * 2018-10-12 2021-02-09 倍而达药业(苏州)有限公司 一种基于SIRP-αD1突变体制备的重组蛋白及应用
SG11202104136YA (en) * 2018-10-23 2021-05-28 Dragonfly Therapeutics Inc Heterodimeric fc-fused proteins
WO2020097193A1 (en) 2018-11-06 2020-05-14 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
CN111303293B (zh) * 2018-11-14 2022-08-30 杭州尚健生物技术有限公司 一种融合蛋白及其用途
CN109517054B (zh) * 2018-12-04 2022-04-08 江苏东抗生物医药科技有限公司 SIRPα变体或其融合蛋白及其应用
BR112021017399A2 (pt) 2019-03-06 2021-11-16 Jiangsu Hengrui Medicine Co Proteína de fusão bifuncional e uso farmacêutico da mesma
JP7249432B2 (ja) * 2019-03-29 2023-03-30 エフ. ホフマン-ラ ロシュ アーゲー 多価分子の機能分析のための、sprをベースとする結合アッセイ
CN111763261B (zh) * 2019-04-02 2022-08-09 杭州尚健生物技术有限公司 一种融合蛋白及其用途
US11026973B2 (en) 2019-04-30 2021-06-08 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
JP2022534212A (ja) * 2019-05-31 2022-07-28 エーエルエックス オンコロジー インコーポレイテッド 免疫チェックポイント阻害剤と組み合わせてsirpアルファfc融合によりがんを治療する方法
CA3142738A1 (en) * 2019-06-05 2020-12-10 Asher Biotherapeutics, Inc. Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function
MA56119A (fr) 2019-06-07 2022-04-13 Alx Oncology Inc Procédés et réactifs pour réduire les interférences de médicaments se liant au cd47 dans des dosages sérologiques
CN112125975B (zh) * 2019-06-25 2024-03-01 上海翰森生物医药科技有限公司 Pd-l1和cd47双特异性融合蛋白及其医药用途
KR20220047277A (ko) 2019-07-16 2022-04-15 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
KR102228271B1 (ko) * 2019-07-16 2021-03-17 한국과학기술연구원 항암활성을 갖는 면역조절 단백질-siRNA 복합체
GB2628935A (en) 2019-09-03 2024-10-09 Myeloid Therapeutics Inc Methods and compositions for genomic integration
EP4045083B1 (en) 2019-10-18 2024-01-10 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
CN114599392A (zh) 2019-10-31 2022-06-07 四十七公司 基于抗cd47和抗cd20的血癌治疗
AU2020394204A1 (en) * 2019-11-27 2022-06-02 ALX Oncology Inc. Combination therapies for treating cancer
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
CN117736207A (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
AU2021207901A1 (en) 2020-01-14 2022-09-08 Synthekine, Inc. IL2 orthologs and methods of use
CN117964757A (zh) 2020-02-14 2024-05-03 吉利德科学公司 与ccr8结合的抗体和融合蛋白及其用途
CN111253482B (zh) * 2020-02-18 2021-11-30 中国人民解放军军事科学院军事医学研究院 SIRPa变体、融合蛋白、及其应用
WO2021191870A1 (en) 2020-03-27 2021-09-30 Dcprime B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
AU2021283083A1 (en) * 2020-06-01 2022-12-01 ALX Oncology Inc. Combination therapies comprising a hypomethylation agent for treating cancer
AU2021301921A1 (en) * 2020-06-30 2023-02-02 Harbour Biomed US, Inc. Bispecific antibody and use thereof
WO2022010806A1 (en) 2020-07-06 2022-01-13 ALX Oncology Inc. Methods for reducing the interference of drugs that bind therapeutic targets expressed on blood cells in serological assays
CN111808183B (zh) * 2020-07-25 2022-07-08 北京吉尔麦迪生物医药科技有限公司 一种靶向CD47的高亲和力SIRPα突变体及其融合蛋白
CN114057888A (zh) * 2020-07-30 2022-02-18 三生国健药业(上海)股份有限公司 一种SIRPα-Fc融合蛋白
JP7538334B2 (ja) * 2020-08-14 2024-08-21 コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー 抗癌活性を有する免疫調節タンパク質-siRNA複合体
KR102579284B1 (ko) * 2020-09-22 2023-09-18 비피진 주식회사 신규의 cd47 바인더와 폴리뉴클레오티드를 포함하는 암 치료를 위한 리포좀 복합체
KR102557016B1 (ko) * 2020-09-22 2023-07-20 비피진 주식회사 암 치료를 위한 cd47 바인더 및 리포좀 복합체
TW202233673A (zh) 2020-10-23 2022-09-01 美商雅雪生物治療公司 含調節免疫細胞功能之cd8抗原結合分子之融合物
JP2023549140A (ja) 2020-11-04 2023-11-22 マイエロイド・セラピューティクス,インコーポレーテッド 操作されたキメラ融合タンパク質組成物およびその使用方法
EP4256336A1 (en) 2020-12-06 2023-10-11 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
CN112979782B (zh) * 2021-03-08 2023-07-18 深圳市乐土生物医药有限公司 一种多肽及其用途
JP2024510989A (ja) 2021-03-12 2024-03-12 メンドゥス・ベスローテン・フェンノートシャップ ワクチン接種方法及びcd47遮断薬の使用
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症
US12098214B2 (en) 2021-05-13 2024-09-24 ALX Oncology Inc. Combination therapies for treating cancer
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20230016152A (ko) * 2021-07-19 2023-02-01 주식회사유한양행 Sirp-alpha 변이체 및 이의 용도
CN113896802A (zh) * 2021-10-09 2022-01-07 宜明昂科生物医药技术(上海)有限公司 靶向cd47和cd38的重组融合蛋白及其制备和用途
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
MX2024005066A (es) 2021-10-29 2024-05-24 Gilead Sciences Inc Compuestos de cd73.
WO2023072279A1 (zh) * 2021-11-01 2023-05-04 江苏先声药业有限公司 SIRPa突变体及其应用
KR20240099484A (ko) 2021-11-19 2024-06-28 한국과학기술연구원 표적 세포로의 활성 제약 성분의 적혈구-매개 전달을 위한 치료 화합물
WO2023088429A1 (zh) * 2021-11-19 2023-05-25 杭州尚健生物技术有限公司 SIRPα变体及其应用
CN116178561A (zh) * 2021-11-26 2023-05-30 杭州尚健生物技术有限公司 包含SIRPα突变体的融合蛋白
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
KR102710779B1 (ko) * 2022-01-04 2024-09-26 주식회사 보령바이오파마 5'-뉴클레오티다아제 변형 단백질을 암호화하는 암 치료를 위한 폴리뉴클레오티드
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7抑制劑
WO2023154578A1 (en) 2022-02-14 2023-08-17 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
IL315083A (en) 2022-03-17 2024-10-01 Gilead Sciences Inc The IKAROS family of zinc fingers degrades and uses them
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
WO2023183890A1 (en) 2022-03-24 2023-09-28 Bitterroot Bio, Inc. Multivalent sirp-alpha fusion polypeptides
WO2023183892A1 (en) 2022-03-24 2023-09-28 Bitterroot Bio, Inc. Sirp-alpha fusion polypeptides with modified fc domains
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
AU2023256670A1 (en) 2022-04-21 2024-10-17 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2023218378A1 (en) 2022-05-11 2023-11-16 Daiichi Sankyo Company, Limited Combination of an antibody specific for a tumor antigen and a cd47 inhibitor
US20240010701A1 (en) 2022-06-01 2024-01-11 ALX Oncology Inc. Combination therapies for treating urothelial carcinoma
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
KR20240034954A (ko) * 2022-09-07 2024-03-15 주식회사 시프트바이오 SIRPα 변이체에 특이적으로 결합하는 항체
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
US20240254118A1 (en) 2022-12-22 2024-08-01 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5697901A (en) 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
JPH04334377A (ja) 1990-12-31 1992-11-20 Akzo Nv 酸−不安定性リンカー分子
EP0590060B1 (en) 1991-06-21 1997-09-17 University Of Cincinnati Orally administrable therapeutic proteins and method of making
US6613332B1 (en) 1991-06-21 2003-09-02 The University Of Cincinnati Oral administration of therapeutic proteins
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5505931A (en) 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AU727531B2 (en) 1995-07-25 2000-12-14 Crucell Holland B.V. Methods and means for targeted gene delivery
AU721034B2 (en) 1996-02-15 2000-06-22 Biosense, Inc. Catheter based surgery
AU3739697A (en) 1996-07-09 1998-02-02 Johns Hopkins University, The Gene delivery system
US6541615B1 (en) 1996-11-15 2003-04-01 Max-Planck-Gellschaft Zur Foderung Der Wissenschaften E.V. SIRP proteins and uses thereof
CA2226962A1 (en) 1998-02-16 1999-08-16 Marie Sarfati Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
EP1192176A4 (en) 1999-06-11 2003-03-05 Human Genome Sciences Inc 49 HUMAN SECRETED PROTEINS
US6613026B1 (en) 1999-12-08 2003-09-02 Scimed Life Systems, Inc. Lateral needle-less injection apparatus and method
GB9930706D0 (en) 1999-12-24 2000-02-16 Medical Res Council Composition for inhibiting macrophage activity
US7662367B2 (en) 2000-03-02 2010-02-16 Xencor, Inc. Pharmaceutical compositions for the treatment of TNF-α related disorders
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
GB0124145D0 (en) 2001-10-08 2001-11-28 Bayer Ag Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
US20040018522A1 (en) 2002-05-09 2004-01-29 Brigham And Women's Hospital, Inc. Identification of dysregulated genes in patients with multiple sclerosis
US7879544B2 (en) 2002-07-29 2011-02-01 Hmgene Inc. Methods of identifying adipocyte specific genes, the genes identified, and their uses
EP1578364A4 (en) 2002-09-16 2011-06-08 Genentech Inc COMPOSITIONS AND METHODS FOR TREATING IMMUNE DISEASES
EP2336179A1 (en) 2002-11-08 2011-06-22 Ablynx N.V. Stabilized single domain antibodies
US20100215640A1 (en) 2003-04-24 2010-08-26 The University Of North Carolina At Chapel Hill Method for inhibiting cellular activation by insulin-like growth factor-1
US20040213792A1 (en) 2003-04-24 2004-10-28 Clemmons David R. Method for inhibiting cellular activation by insulin-like growth factor-1
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
EP1658308A1 (en) 2003-08-25 2006-05-24 Pieris ProteoLab AG Muteins of a bilin-binding protein with affinity for a given target
WO2005084198A2 (en) 2004-02-27 2005-09-15 Vaxconsulting Peptides of il1 beta and tnf alpha and method of treatment using same
WO2005092362A2 (de) 2004-03-29 2005-10-06 Hallstroem Seth Pharmazeutisches kombinationspräparat enthaltend ein therapeutisches protein
US20080299042A1 (en) 2004-04-30 2008-12-04 Biogen Idec Ma Inc. Membrane Associated Molecules
US7514229B2 (en) 2005-09-29 2009-04-07 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and evaluating treatment of blood disorders
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
TW200848429A (en) * 2007-04-23 2008-12-16 Wyeth Corp Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
CA2697032C (en) 2007-08-22 2021-09-14 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
EP2388270A3 (en) 2007-10-11 2012-04-25 The Hospital For Sick Children Modulation of SIRPa - CD47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
HUE028536T2 (en) 2008-01-07 2016-12-28 Amgen Inc Method for producing antibody to FC heterodimer molecules using electrostatic control effects
ES2582340T3 (es) 2008-01-15 2016-09-12 The Board Of Trustees Of The Leland Stanford Junior University Métodos para manipular fagocitosis mediada por CD47
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
KR20110112299A (ko) 2008-12-19 2011-10-12 노파르티스 아게 자가면역 및 염증성 장애의 치료에 사용하기 위한 가용성 폴리펩티드
CN102482347B (zh) 2009-01-12 2017-04-26 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
PL2429574T3 (pl) 2009-05-15 2015-12-31 Univ Health Network Kompozycje i sposoby leczenia nowotworów hematologicznych celujące w oddziaływanie SIRP-CD47
RU2547592C2 (ru) 2009-07-20 2015-04-10 Нэйшнл Ченг Кунг Юниверсити ПОЛИПЕПТИДЫ, СЕЛЕКТИВНЫЕ В ОТНОШЕНИИ ИНТЕГРИНА αvβ3, КОНЪЮГИРОВАННЫЕ С ВАРИАНТОМ ЧЕЛЕВЕЧЕСКОГО СЫВОРОТОЧНОГО АЛЬБУМИНА (HSA), И ИХ ФАРМАЦЕВТИЧЕСКИЕ ПРИМЕНЕНИЯ
KR101632312B1 (ko) 2009-11-03 2016-06-21 삼성전자주식회사 항체 불변 영역에 특이적으로 결합하는 융합 단백질, 그의 제조 방법 및 이를 이용한 항체 분리 방법
CN102711810B (zh) * 2009-11-30 2015-04-22 詹森生物科技公司 效应子功能已消除的抗体Fc区突变体
AU2010334974A1 (en) 2009-12-22 2012-07-12 Novartis Ag Tetravalent CD47-antibody constant region fusion protein for use in therapy
PT2569013T (pt) 2010-05-14 2017-02-08 Univ Leland Stanford Junior Anticorpos monoclonais humanizados e quiméricos para cd47
CN103501815B (zh) 2010-10-08 2016-09-28 希望之城公司 针对中间位的单克隆抗体框架结合界面、中间位投递系统及其使用方法
US8609621B2 (en) 2010-11-15 2013-12-17 E I Du Pont De Nemours And Company Acid-cleavable linkers exhibiting altered rates of acid hydrolysis
WO2012109267A2 (en) 2011-02-07 2012-08-16 The Trustees Of The University Of Pennsylvania Novel peptides and methods using same
HUE041335T2 (hu) 2011-03-29 2019-05-28 Roche Glycart Ag Antitest FC-variánsok
PL2697257T3 (pl) 2011-04-13 2017-04-28 Bristol-Myers Squibb Company Białka fuzyjne fc o nowatorskim układzie lub zawierające nowatorskie łączniki
JP2014518615A (ja) * 2011-04-22 2014-08-07 エマージェント プロダクト デベロップメント シアトル, エルエルシー 前立腺特異的膜抗原結合タンパク質および関連組成物ならびに方法
JP2014519338A (ja) 2011-06-16 2014-08-14 ノバルティス アーゲー 治療薬として使用される可溶性タンパク質
US20140242095A1 (en) 2011-10-19 2014-08-28 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
WO2013063076A1 (en) 2011-10-25 2013-05-02 Indiana University Research & Technology Corporation Compositions for and methods of modulating complications, risks and issues with xenotransplantation
ES2816647T3 (es) 2012-01-17 2021-04-05 Univ Leland Stanford Junior Reactivos SIRP-alfa de alta afinidad
US9428553B2 (en) 2012-02-10 2016-08-30 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
WO2013192546A1 (en) 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and mehtods of using the same
AU2013278075B2 (en) 2012-06-22 2018-05-17 Cytomx Therapeutics, Inc. Anti-jagged 1/Jagged 2 cross-reactive antibodies, activatable anti-Jagged antibodies and methods of use thereof
GB201216649D0 (en) 2012-09-18 2012-10-31 Univ Birmingham Agents and methods
ES2755156T3 (es) 2012-12-17 2020-04-21 Trillium Therapeutics Inc Tratamiento de células enfermas CD47+ con fusiones SIRP alfa-Fc
US9873747B2 (en) 2013-01-31 2018-01-23 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
PL4119153T3 (pl) 2013-02-05 2024-09-02 The Board Of Trustees Of The Leland Stanford Junior University Terapie ukierunkowane na cd47 w leczeniu choroby zakaźnej
WO2014160183A1 (en) 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
EP2970493B1 (en) 2013-03-15 2019-04-03 The Board of Trustees of the Leland Stanford Junior University Methods for achieving therapeutically effective doses of anti-cd47 agents
WO2014179132A1 (en) 2013-04-29 2014-11-06 The Board Of Trustees Of The Leland Stanford Junior University Use of anti-cd47 agents to enhance immunization
US9945870B2 (en) 2013-05-17 2018-04-17 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-CD47 agent
WO2015017548A2 (en) * 2013-07-31 2015-02-05 Amgen Inc. Stabilization of fc-containing polypeptides
ES2765483T3 (es) 2013-09-18 2020-06-09 Univ Leland Stanford Junior Modulación de las vías de eferocitosis para el tratamiento de una enfermedad aterosclerótica
US9193977B2 (en) 2013-09-23 2015-11-24 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized signal-regulatory protein gene
CN118146306A (zh) 2013-09-25 2024-06-07 西托姆克斯治疗公司 基质金属蛋白酶底物和其它可切割部分及其使用方法
ES2845924T3 (es) * 2013-10-15 2021-07-28 Scripps Research Inst Interruptores de células T con receptores de antígenos quiméricos peptídicos y usos de los mismos
IL302642A (en) 2014-01-31 2023-07-01 Cytomx Therapeutics Inc Polypeptide substrates that activate matriptase and U-plasminogen and other cleavable groups, preparations containing them and their uses
CN114081946A (zh) 2014-03-12 2022-02-25 耶达研究与开发有限公司 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
WO2016023001A1 (en) 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Multispecific high affinity pd-1 agents and methods of use
WO2016022994A2 (en) 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University High affinity pd-1 agents and methods of use
WO2016023040A1 (en) * 2014-08-08 2016-02-11 Alexo Therapeutics International Sirp-alpha variant constructs and uses thereof
ES2962260T3 (es) 2014-08-08 2024-03-18 Univ Leland Stanford Junior Proteínas de fusión SIRPa alfa-anticuerpo
SG11201701189TA (en) 2014-08-15 2017-03-30 Merck Patent Gmbh Sirp-alpha immunoglobulin fusion proteins
EP3822364B1 (en) 2014-08-26 2023-05-10 The Board of Trustees of the Leland Stanford Junior University Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling
CA2958898A1 (en) 2014-09-15 2016-03-24 The Board Of Trustees Of The Leland Stanford Junior University Targeting aneurysm disease by modulating phagocytosis pathways
EP3204420B1 (en) 2014-10-10 2020-09-02 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods to eliminate cancer stem cells by targeting cd47
US10316094B2 (en) 2014-10-24 2019-06-11 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistance
EP3012271A1 (en) 2014-10-24 2016-04-27 Effimune Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
MX2017006485A (es) 2014-11-18 2018-03-23 Janssen Pharmaceutica Nv Anticuerpos anti-cd47, metodos y usos.
ES2838925T3 (es) 2015-02-27 2021-07-02 Univ Leland Stanford Junior Terapia de combinación para el tratamiento de la ateroesclerosis
CN106146670B (zh) 2015-04-24 2019-01-15 宜明昂科生物医药技术(上海)有限公司 一种新的重组双功能融合蛋白及其制备和应用
GEP20217326B (en) 2015-08-07 2021-11-25 Alx Oncology Inc Constructs having a sirp-alpha domain or variant thereof
SG11201808465UA (en) 2016-04-14 2018-10-30 Ose Immunotherapeutics NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
JP2022534212A (ja) 2019-05-31 2022-07-28 エーエルエックス オンコロジー インコーポレイテッド 免疫チェックポイント阻害剤と組み合わせてsirpアルファfc融合によりがんを治療する方法
MA56119A (fr) 2019-06-07 2022-04-13 Alx Oncology Inc Procédés et réactifs pour réduire les interférences de médicaments se liant au cd47 dans des dosages sérologiques
AU2020394204A1 (en) 2019-11-27 2022-06-02 ALX Oncology Inc. Combination therapies for treating cancer
AU2021283083A1 (en) 2020-06-01 2022-12-01 ALX Oncology Inc. Combination therapies comprising a hypomethylation agent for treating cancer
WO2022010806A1 (en) 2020-07-06 2022-01-13 ALX Oncology Inc. Methods for reducing the interference of drugs that bind therapeutic targets expressed on blood cells in serological assays
EP4256336A1 (en) 2020-12-06 2023-10-11 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
US12098214B2 (en) 2021-05-13 2024-09-24 ALX Oncology Inc. Combination therapies for treating cancer

Also Published As

Publication number Publication date
CN117777267A (zh) 2024-03-29
SA518390881B1 (ar) 2021-11-14
PH12018500269A1 (en) 2018-08-29
IL294679A (en) 2022-09-01
CL2018000340A1 (es) 2018-05-11
AU2021218004B2 (en) 2023-06-15
WO2017027422A1 (en) 2017-02-16
HRP20211167T1 (hr) 2021-10-15
IL294679B1 (en) 2023-06-01
CN108350048A (zh) 2018-07-31
HK1257372A1 (zh) 2019-10-18
US20240343778A1 (en) 2024-10-17
EP3913051A1 (en) 2021-11-24
JP6898303B2 (ja) 2021-07-07
CN117964732A (zh) 2024-05-03
ZA202000743B (en) 2022-07-27
US10259859B2 (en) 2019-04-16
CN108350048B (zh) 2024-02-09
HUE055139T2 (hu) 2021-11-29
ZA201800857B (en) 2020-10-28
MX2022010803A (es) 2022-09-27
PT3331902T (pt) 2021-07-26
IL256989B (en) 2022-08-01
IL294679B2 (en) 2023-10-01
SG10201912905VA (en) 2020-02-27
LT3331902T (lt) 2021-08-10
AU2016304794B2 (en) 2021-07-15
US11208459B2 (en) 2021-12-28
NZ738950A (en) 2023-03-31
JP2021063082A (ja) 2021-04-22
CL2020000531A1 (es) 2020-07-10
KR20180028548A (ko) 2018-03-16
ZA202001863B (en) 2023-12-20
RU2018108103A3 (sr) 2019-12-20
CL2020000530A1 (es) 2020-07-10
JP2018525382A (ja) 2018-09-06
UA125638C2 (uk) 2022-05-11
RU2020143675A (ru) 2021-05-26
BR112018001353A2 (pt) 2018-09-11
EP3331902B1 (en) 2021-04-28
MX2018001428A (es) 2018-09-05
EP3331902A4 (en) 2019-04-03
PE20180778A1 (es) 2018-05-07
SG10202101909RA (en) 2021-04-29
US11639376B2 (en) 2023-05-02
IL256989A (en) 2018-03-29
DK3331902T3 (da) 2021-07-26
ES2881771T3 (es) 2021-11-30
MY185014A (en) 2021-04-30
CO2018002471A2 (es) 2018-05-31
AU2016304794A1 (en) 2018-02-01
US20200239543A1 (en) 2020-07-30
US10696730B2 (en) 2020-06-30
EP3331902A1 (en) 2018-06-13
GEP20227447B (en) 2022-12-12
CY1124372T1 (el) 2022-07-22
US20170107270A1 (en) 2017-04-20
US20210070838A1 (en) 2021-03-11
PL3331902T3 (pl) 2021-11-22
SI3331902T1 (sl) 2021-09-30
AU2021218004A1 (en) 2021-09-09
RU2018108103A (ru) 2019-09-09
CA2993835A1 (en) 2017-02-16
IL302491A (en) 2023-06-01
JP2023061969A (ja) 2023-05-02
RU2020143675A3 (sr) 2021-10-29
GEP20217326B (en) 2021-11-25
US20190169266A1 (en) 2019-06-06
RU2740672C2 (ru) 2021-01-19

Similar Documents

Publication Publication Date Title
ZA202001863B (en) Constructs having a sirp-alpha domain or variant thereof
HUE049290T2 (hu) Leválasztó
IL273493A (en) Modified CAR-T
EP3684343C0 (en) IMPROVED SUPRAPARTICLES
GB201612093D0 (en) Combination
IL272526A (en) Enhanced endoinulinase proteins
IL252511A0 (en) An element capable of injecting light
PL3113960T3 (pl) Element mocujący
GB201616014D0 (en) Combination
GB201707210D0 (en) Improved hitchlock
GB201610869D0 (en) Combination
GB201716492D0 (en) Disclosure
GB201715938D0 (en) Disclosure
GB201715756D0 (en) Disclosure
GB201706691D0 (en) Microcontroller
GB201713289D0 (en) Combination
GB201707508D0 (en) Modified bulgeomers
PT3308671T (pt) Vassoura
GB201709193D0 (en) Combination
GB201709567D0 (en) Chimp
GB201703034D0 (en) Modified bulgeomers
GB201706929D0 (en) Combination
GB201621467D0 (en) Modified bulgeomers
GB201616374D0 (en) Modified bulgeomers
GB201614858D0 (en) Modified Bulgeomers